ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

SBTX Skinbiotherapeutics Plc

10.20
0.05 (0.49%)
21 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Skinbiotherapeutics Plc LSE:SBTX London Ordinary Share GB00BF33H870 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.05 0.49% 10.20 10.25 10.60 10.425 10.15 10.15 1,286,917 16:35:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Biological Pds,ex Diagnstics 132k -2.84M -0.0163 -6.39 18.13M
Skinbiotherapeutics Plc is listed in the Biological Pds,ex Diagnstics sector of the London Stock Exchange with ticker SBTX. The last closing price for Skinbiotherapeutics was 10.15p. Over the last year, Skinbiotherapeutics shares have traded in a share price range of 7.25p to 29.50p.

Skinbiotherapeutics currently has 174,004,323 shares in issue. The market capitalisation of Skinbiotherapeutics is £18.13 million. Skinbiotherapeutics has a price to earnings ratio (PE ratio) of -6.39.

Skinbiotherapeutics Share Discussion Threads

Showing 8201 to 8223 of 23750 messages
Chat Pages: Latest  338  337  336  335  334  333  332  331  330  329  328  327  Older
DateSubjectAuthorDiscuss
02/1/2021
16:50
1marcr, I never said you were aiming at anybody, that's why I asked who, appologies if it came across that way. It's just that you said "the comms that I have come across"
toyin
02/1/2021
16:38
My comments weren't aimed at Elric, just how enthusiastic SA is about the trial (which as I CEO I guess he should be). My point was let's not get too excited just yet in case the trial isn't a success.
1marcr
02/1/2021
16:09
It is an if not when but winclove and prof cath are experts and must be happy with the method of action of the mix.

Also this isn’t about a cure it’s about alleviating the symptoms., so it gives a real wide target of success.

Even slight relief will be classed as successful when the price pitch is £1 per day.

More to this than a pass or a fail imo.

S

shrewdmole
02/1/2021
16:05
1marcr, I would like to know were your information comes from re the "if" and "when".
I know from conversations and emails with Elric we are both in the "if" camp, from memory I dont remember SA every saying it was a "when" outcome. If it was a givin that it works what would be the need for the trials! Who are the people saying "when" and who is being lined up for a fall?

toyin
02/1/2021
15:20
I think elrico eluded to this with a capital IF. and also stated it would represent a key DERISK moment. If that isn't a warning the human trials are not 100% certain to be a success i don't know what is.
slartybartfaster
02/1/2021
14:17
Happy new year guys. I can understand where PJ is coming from. The comms that I have come across surrounding the upcoming psoriasis trail is not an 'if' the trial is successful but a 'when'. My worry as an investor is are we unintentionally being set up for a fall, if the trial doesn't work as hoped? On the flip side if the trial does work then I think we will all profit very handsomely from it.
1marcr
02/1/2021
13:54
PJ, ref AVA. It has. I have several PM's suggesting investment-grade activity.
elrico
02/1/2021
13:09
refer to IMM.
pj 1
02/1/2021
13:06
Clearly indicating that you neither understand the science or the market. As Shrewd has already said..... one of the biggest and most successful UK businesses, Croda, a FTSE 100 company, have committed millions to a production line and you see the share price at 9p. That's without all of the other channels. Do us all a favour and sell your stock, if you actually hold any.
madaboutmed
02/1/2021
13:01
shrewdie, yes fair comment, it was a little tongue in cheek, my comments were solely based on the spring trial.

On a serious note I now prefer to base any estimates I have on tangible figures and official RNS statements.

edit- as an aside, I'm astounded Elrics comments on AVA have not generated more interest in the Company.

pj 1
02/1/2021
13:00
PJ, you're the sort of person that can brighten up any room...once you've left! 🤣🤣

Can you please start a new, more positive 2021, if only for your sake. You're gonna give yourself ulcers they way you carry on, or worse, trick yourself into selling.

elrico
02/1/2021
12:54
Pj

I know your cynical but you seem to totally discount croda/sederma who have committed millions to a dedicated production line that has replicated the method of action.
You’ve also totally discounted any further IP for hair and oral care, cleanbiotix or woundcare or any up front payments.

Let’s not forget SA options kick in above 30p.

shrewdmole
02/1/2021
12:35
Shrewd I can see us at 75p if everything
goes according to plan.
As we went up to around 27p not that long ago
I think we could easily be twice that and more.
Just for FUN.

1crunchy
02/1/2021
12:18
OK - 42p, but I think we will surpass 50p at some point earlier in the year, assuming positive news on the trial, of course.
I hope your prediction is closer than mine though!

lovewinshatelosses
02/1/2021
11:52
Right then following elrics tips let’s just for fun put a 31st December 2021 price guesstimate for sbtx!!

I’m going for 85p.

Like I say just for fun.

S

shrewdmole
01/1/2021
23:37
Donated today Elrico
robo28
01/1/2021
22:23
$ORPH
$SNG
$SBTX
$DDDD
$OPTI
$AVA

$PHE

elrico
01/1/2021
16:29
Proactive are wrong. Elrico teases out the real time line though his relaxed approach allowing the CEO to talk freely without interruption. Both croda and winclove could have commercial products by October. Both limited 25k to 50k subscribers for the psoriasis and 12 VIP cosmetic brands. Listen to Stuart Ashman CEO SkinBioTherapeutics by lemming investors on #SoundCloudhTTps://soundcloud.app.goo.gl/g8mfx
slartybartfaster
01/1/2021
14:53
Robbie, it is good exposure but its a bad article. It states:

"This will commence in the first quarter of 2021.

"If this is successful, AxisBiotix could become a commercial food supplement by early-2022.

This is incorrect, if successful it will be commercial in Q3/Q4 2021 in limited numbers initially, between 25-50,000 subscribers. If we take the low figure of 25k that gives us £9.1m pa for starters.

If 1% of the states use it, that is 80,000 people X £1 per day = £29.2m pa

If 1% of the UK use it, that is 11,000 people X £1 per day = £4m pa

If 1% of the world use it, that is 1.25m people X £1 per day = £456m pa

SA did lay some of this out in his last interview with Elric.

Apologies if my calcs are out, had a couple of glasses of Chablis😬


Happy New Year everyone.

toyin
01/1/2021
14:53
The CEO SA needs to play this down and keep us in reality. This reminds me exactly of IMM a few years ago.

Its pretty obvious to me what's going top happen here at some point.

pj 1
01/1/2021
13:19
Been tipped again for 2021.



if the psoriasis trial delivers then the sky is the limit. If just 1% of the psoriasis group in the states start using the product then it will pull in around £11m per annum. It is the type of product that if it delivers the results we all hope then he uptake will be vastly more than 1%. Drop the rest of the world market in on top then it might be challenging to keep up with demand!

Then we throw the Croda deal in and boom

robbieishere
31/12/2020
09:08
Must be a large buy to be reported later.
rafboy
31/12/2020
09:05
Don't see that very often. Bid and Offer both at 23p.
zedder
Chat Pages: Latest  338  337  336  335  334  333  332  331  330  329  328  327  Older

Your Recent History